ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

SAR Sareum Holdings Plc

27.50
-3.00 (-9.84%)
Last Updated: 10:16:21
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Sareum Holdings Plc LSE:SAR London Ordinary Share GB00BMC3RJ87 ORD GBP 0.0125
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -3.00 -9.84% 27.50 27.00 28.00 30.50 27.50 30.50 1,295,607 10:16:21
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 0 -3.19M -0.0469 -5.97 19.06M
Sareum Holdings Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker SAR. The last closing price for Sareum was 30.50p. Over the last year, Sareum shares have traded in a share price range of 10.20p to 147.50p.

Sareum currently has 68,069,416 shares in issue. The market capitalisation of Sareum is £19.06 million. Sareum has a price to earnings ratio (PE ratio) of -5.97.

Sareum Share Discussion Threads

Showing 11276 to 11296 of 17225 messages
Chat Pages: Latest  461  460  459  458  457  456  455  454  453  452  451  450  Older
DateSubjectAuthorDiscuss
28/5/2022
20:51
What does the UEFA Champions League have to do with immune based therapies? 😜
norma_stitts
28/5/2022
17:54
Just watched a segment on GB news re UCL and immune based therapies. Looking at monies raised due to Prof Janet Thornton and fighting cancer. Found this RNS extract from Sareum 2005 of which we were involved!
Inpharmatica’s initial technology was based on research from Professor Janet Thornton’s group at University College London. The Company employs approximately 100 professionals at its UK locations in London and Cambridge, with business development headed in North America. Inpharmatica has raised some £35.0m from leading venture capitalists and has sales/collaboration partnerships with Serono, Pfizer, GSK, Aventis, Daiichi, Riken, Taisho, UCB Pharma, MDL, Ionix, CellZome and Galapagos.
Seems to me a lot of big names are dovetailing re immunotherapy treatment and Sareum are definitely part of the group albeit not being named.
Tyk tok.
Regards CT

criticalthinker1
28/5/2022
09:06
Well basically all I understand us MPG and that fuel costs too much we shall see what it looks like after 10 days running round up here although it's mostly country lane driving.Critical the share price does what it likes can't say I am a great believer in it being manipulated all the time. Sometimes maybe when a big buy is going through but I don't believe all these figures that go through and deffo not the colour of trades. The warrant issue is intriguing but could that be for introducing the HNWIs to us and them having stayed with us. You could be right in that they have been setting something else up as well.As for TR1 issue different rules apply in different countries and I think they differ by ordinary PI and II investment.Nobody has explained to me why none appeared in the week a billion shares in SAR traded two years ago.
silvergreyhead1
27/5/2022
21:39
It's why I had squeaky bum time when petrol shortage was on. Car can only run on 99 octane.
madd_rip
27/5/2022
19:11
Hi Silver. Have a great getaway. Word of advice re fuel. Don't use E10 in your vehicle or garden machinery. Because its 10% ethanol it draws moisture and affects o rings etc that are plastic based which then degrade.
Second point. What's your opinion on the share price staying stagnant yet the buys are extremely superior? Do you think PH are buying what they can and filling iis fill orders. Surely given the time this has been going on a TR1 is incoming given just over 2m shares required. Makes me think about some holders who claim to hold certain large volumes yet have not been mentioned in a TR1! Maybe the 29m share option 'thanks' to 'introducers' which can be purchased when share price hits x but post consolidation equates to 580k, Something is happening. Those continued buys before would have seen a significant share price rise. I'm waiting for the big bang. Q3? ;-) ?
Anyhows have a great holiday. CT

criticalthinker1
27/5/2022
18:33
Here's a boring one for youOld E5 petrol used to get 46 mpg combinedNew E10 petrol absolutely sh.t down to 40 mpg com.Super E5 petrol 48 mpg com. so started using that okay it was around 5% more but got 20% better mileage than E10 sh.tSo this week did a halfy halfy filled half with E5 and half with E10 two different garages so as not to look a Pillock. About to refill tomorrow and running at 52 mpg. Slightly more Mway in this time but Louise does that driving and if she's below 75 mph the are in roadworks or volume.So if Critical can write sh.te we all can. Have a great weekend folks I am up in sunny Belford for ten days on the beer and the beaches( Only playing critical keep posting mate )
silvergreyhead1
27/5/2022
12:19
No - my mates know me as Johann Wolfgang von Goethe, you can call me Barkers. lol
barkbooo
27/5/2022
12:17
are you Rebecca Vardy ?
horridhenry
27/5/2022
11:37
horridhenry - I am more innocent until proven guilty kinda guy...but you can never be too careful.

If you thought this thread had rags - the vetting necessary on our TRMR thread is like a week at the Old Bailey!

barkbooo
27/5/2022
10:05
Silver he's a frog kisser. He is much better off on LSE where there are loads of them
horridhenry
26/5/2022
21:37
Also just an additional point. GSK advised they needed to appoint more directors with scientific backgrounds.
Now where did we here one of our board say discussions recently with 'x' say that discussions were held but further discussions were required at a later date. Wink wink.
Best regards CT

criticalthinker1
26/5/2022
21:17
Thankyou Norma. Just thought we might have had an update re flt3 data as Sareum BOD advised.
Anyhow this re GSK turning down Nestle £50billion offer ( with what could of been Reckitt being involved) Quite interesting re "pipeline"
Haleon is an attractive consumer asset, which should ultimately be reflected in its independent valuation,” analysts at Jefferies Financial Group Inc. wrote in a note Thursday, citing the potential takeover interest.

The report “suggests̶1; GSK is committed to the spinoff as a tax-free way of crystallizing value for shareholders while also providing £7 billion to pursue pipeline deals, without the potential delays from a sale, according to Jefferies.
The report today also advises that Elliot is keen on getting pipeline drugs into GSK ownership.
Something is brewing for Sareum I'm convinced.
Regards CT

criticalthinker1
26/5/2022
17:24
Barkboo voted for him last time to get Brexit done. Without getting into any political or behavioural arguments for me his and Sunaks time is well gone now.Vote Super Frankie Lampard from now!And of course that is with the greatest respect to yours and everyone's opinions on here, don't want Horrid getting on at me.
silvergreyhead1
26/5/2022
16:34
Silver - I like Boris..he plays the remoaner idiots in our press to perfection.

They think they are beating him, look at his political career - he never loses, and never shouts about that. lol

Silver I respect your views whatever.

barkbooo
26/5/2022
16:17
Just wish SAR would realise it's true value soon. Then I can tell Sunak Boris and the likes to just f.ck off
silvergreyhead1
25/5/2022
21:14
Criticalthinker1, It was never announced who the Chinese pharma was.

Was handed back as they couldn’t resolve solubility issues along with extra data. IIRC they only paid £50k upfront, which for me, was indicative that they didn’t hold high hopes of resolving it.

norma_stitts
25/5/2022
20:47
Also this re FLT3 26th March 2020 RNS
Sareum Holdings plc (AIM: SAR), the specialist cancer drug discovery and development business, is pleased to announce that it has entered into an agreement (the “AgreementR21;) with a China-based specialty pharmaceutical company (the “Licensee).
Anybody know who the specialist pharma company is? There's a storm brewing if you read more than msm. If our BOD say they have the research and we're going to investigate flt3 why have we heard nothing. And don't say they don't have funds!

criticalthinker1
25/5/2022
19:34
Hi silver. But given the addition and then departing of kowalski at SO (forgot his correct name) which Sareum in a RNS stated they were very happy with regards to his acknowledgement of pipeline drugs at SO. I'm wondering if 737 has had a bit more attention than we know. Interesting times.
Also if they bought 737 solely as a drug from CRUK and Sareum via SO would that not get the jungle drums beating!?
Just seeing the trades at Sareum for about 6 weeks I'm convinced the newly introduced corporate advisors are keeping a lid on the share price
Will it be to benefit the iis via shareholders getting bored and selling? Something is happening. The trades and spread and share price speaks volumes of market control due to incoming news.
My opinion CT

criticalthinker1
25/5/2022
18:28
Hello Critical the GSK buying Sierra to secretly get 737 theory is rife on LSE. Personally don't buy it if they wanted 737 to they could have bought it on its own for a lot less. My hope is the CPR are onto GSK as soon as the TO is finalised as to their intention in regards to 737. Probably not they are a charity and can continue on without cash from 737 SAR are a business and could do with 737 progressing to a revenue stream. 737 if all reports are true could help a lot of pigging people get some relief from this awful disease.I do see some sense in the argument that GSK may sell on 737 to another big pharma, apparently one has removed references to 737 from it's website, conspiracy or what?
silvergreyhead1
25/5/2022
17:28
So this extract from GSK RNS 13th April 2022 re potential T/O of SO. Note they talk about Mom but don't hide the other main two pipeline drugs.
About Sierra Oncology

Sierra Oncology is a late-stage biopharmaceutical company based in San Mateo, California, on a mission to deliver targeted therapies that treat rare forms of cancer. In addition to momelotinib, the pipeline consists of two assets in phase I SRA515 and SRA737. SRA515 is a selective bromodomain-containing protein 4 (BRD4) bromodomain and extra-terminal domain (BET) inhibitor with a novel bivalent binding mode that inhibits both protein bromodomains, and SRA737 is a novel checkpoint kinase 1 (CHK1) inhibitor.
Just wondering if the new appointment re AI is to get 737 a fanfare at some point.
Best regards CT

criticalthinker1
25/5/2022
17:17
Greatly appreciate your response silver. Like to add this re GSK and SRA737 4th May 2022 re new appointment and how they might be using his expertise to fast track pipeline drugs

Vishal has a distinguished background in technology and particularly in the field of Artificial Intelligence (AI) and Machine Learning, which is central to GSK's approach to R&D
Going to add what GSK said re SRA 737 re the SO potential T/O

criticalthinker1
Chat Pages: Latest  461  460  459  458  457  456  455  454  453  452  451  450  Older

Your Recent History

Delayed Upgrade Clock